Spiropiperidine Derivatives for Selective FASN Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by Fatty Acid Synthase (FASN) expression, such as cancer, metabolic disorders, and viral infections, lack effective and specific inhibitors that target FASN to modulate lipid metabolism and immune responses.
Innovation Solution
Development of compounds according to Formula I, including their stereoisomeric forms and pharmaceutically acceptable salts, which act as FASN inhibitors to treat conditions mediated by FASN expression, such as cancer, metabolic disorders, and viral infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FASN inhibitors are developed to treat conditions mediated by FASN expression, then therapeutic efficacy is improved, but drug specificity and selectivity become critical challenges
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that target particular regions or conformations of the FASN enzyme. The compounds of Formula I contain specific substituent patterns (R1-R6 groups) that are optimized to interact with unique pockets or residues in the FASN active site, thereby achieving high specificity while maintaining potent inhibition of the target enzyme.
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters of the inhibitor molecules (such as substituent types, ring sizes, and spatial configurations) to optimize the balance between binding affinity to FASN and selectivity against off-target enzymes. This allows fine-tuning of the inhibitor properties to achieve both high efficacy and minimal off-target effects.
2Adaptability or versatility
If broad-spectrum FASN inhibitors are used to treat multiple conditions, then versatility is improved, but side effects and toxicity increase
Solution Approach 1:
The patent applies universality by developing FASN inhibitors with a core molecular scaffold (Formula I) that can effectively treat multiple conditions mediated by FASN expression, including cancer, metabolic disorders, and viral infections. The compounds demonstrate broad-spectrum activity against diverse pathologies while maintaining a consistent mechanism of action through selective FASN inhibition.
Solution Approach 2:
The patent employs structure-activity relationship optimization where specific substituent combinations (R1-R6 groups) are designed to maximize therapeutic window. By carefully selecting substituents that enhance FASN binding while minimizing interactions with other biological targets, the compounds achieve broad efficacy with reduced off-target toxicity, effectively creating highly selective inhibitors for each application.
Data Source
AI summary
Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.